
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee by a unanimous vote recommended that the FDA issue an emergency use authorization that would enable COVID-19 vaccine boosters for individuals age 65 and older and those at high risk for severe COVID-19, administered at least six months after a completed initial two-dose mRNA regimen.